Details for Patent: 9,611,267
✉ Email this page to a colleague
Which drugs does patent 9,611,267 protect, and when does it expire?
Patent 9,611,267 protects PEMAZYRE and is included in one NDA.
This patent has one hundred and eleven patent family members in thirty-seven countries.
Summary for Patent: 9,611,267
| Title: | Substituted tricyclic compounds as FGFR inhibitors |
| Abstract: | The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer. |
| Inventor(s): | Wu; Liangxing (Wilmington, DE), Zhang; Colin (Ambler, PA), He; Chunhong (Chadds Ford, PA), Lu; Liang (Hockessin, DE), Yao; Wenqing (Chadds Ford, PA) |
| Assignee: | Incyte Holdings Corporation (Wilmington, DE) Incyte Corporation (Wilmington, DE) |
| Application Number: | 13/915,775 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 9,611,267
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-001 | Apr 17, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-002 | Apr 17, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-003 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,611,267
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2861595 | ⤷ Subscribe | PA2021519 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | 301131 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | LUC00222 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | CA 2021 00033 | Denmark | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | 122021000054 | Germany | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | 2021C/536 | Belgium | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | C02861595/01 | Switzerland | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
